Study of Olutasidenib and Temozolomide in HGG

High Grade Glioma Clinical Trial

Official title:

Phase 2 Study of Olutasidenib With Temozolomide as Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06161974
• Other study ID #: TarGeT-D
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 2024
• Est. completion date: June 2035

Study information

• Verified date: March 2024
• Source: Rigel Pharmaceuticals
• Contact: Elizabeth Franklin
• Phone: 650-624-1100
• Email: clinicaltrials[@]rigel.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation.

The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.

Description:

This is a multicenter, international, phase II study of post-radiotherapy (RT) administration of olutasidenib to treat pediatric and young adult patients newly diagnosed with an IDH1-mutant HGG. The trial will include a feasibility cohort to identify the dose of olutasidenib that is feasible when given in combination with temozolomide as maintenance therapy after completion of focal radiotherapy in this patient population.

Efficacy will be defined by progression-free survival (PFS) distribution of these patients after completion of radiotherapy treated with maintenance olutasidenib and TMZ for 13 cycles followed by 13 cycles of single agent olutasidenib compared to molecularly-stratified and matched historical controls.

Objective radiographic response rates, agent-specific toxicities as well as the pharmacokinetic and pharmacodynamic properties of olutasidenib will also be assessed.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: June 2035
• Est. primary completion date: June 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 39 Years

Eligibility

Criteria TarGeT-D study strata definitions

• Stratum A: Patients with localized, intracranial, non-pontine, and non-thalamic IDH 1 mutant Astrocytoma, CNS WHO Grade 3.

• Stratum B: Patients with localized, intracranial, non-pontine, and non-thalamic IDH 1 mutant Astrocytoma, CNS WHO Grade 4.

• Stratum C: Patients with IDH-1 mutant DIPG, primary thalamic and spinal cord IDH-1 mutant HGG.

Inclusion Criteria:

1. Inclusion criteria already met to enroll on TarGeT-SCR (central molecular and histopathologic screening) based on:

1.1) Age: patients must be =12 years and =39 years of age at the time of enrollment on TarGeT-SCR

1.2) Diagnosis:

• Patients with a newly-diagnosed IDH1-mutant HGG including DIPG are eligible. All patients must have tumor tissue from diagnostic biopsy or resection, without exceptions. The diagnosis of HGG, including DIPG, must have been confirmed through TarGeT-SCR.

• For the diagnosis of DIPG, patients must have a tumor with pontine epicenter and diffuse involvement of at least 2/3 of the pons, and histopathology consistent with diffuse WHO Grade 2-4 glioma.

• All other HGG must be WHO Grade 3 or 4.

1.3) Disease status: There are no disease status requirements for enrollment

• Measurable disease is not required. Patients without measurable disease are eligible.

• Primary spinal tumor: Patients with a primary spinal HGG are eligible.

• Patient must not have metastatic disease.

2. Inclusion criteria for assignment to TarGeT-D, for all strata:

2.1 Presence of at Least One Relevant Actionable Somatic Mutation in IDH1 Gene, Detailed Here:

• R132H, R132C, R132S, R132G or R132L.

• Patients whose tumors harbor other alterations in addition to IDH1 mutation will potentially be eligible following consensus recommendation by the international multidisciplinary molecular screening committee.

• Patients with IDH2 mutations are not eligible.

• Patients with oligodendroglioma, IDH-mutant and 1p/19q-codeleted are not eligible.

2.2 Performance Level: Karnofsky = 50% for patients > 16 years of age and Lansky = 50 for patients = 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

2.3 Prior Therapy

2.3.1 Surgery, radiation, and/or dexamethasone are permissible. Temozolomide administered concurrently with radiotherapy is permissible. No other prior anticancer therapy for HGG will be allowed.

2.3.2 Radiation therapy requirements: RT, delivered via photon or proton beam, must have been administered at a standard dose including 54 Gy in 30 fractions for DIPG, 59.4 Gy in 33 fractions or 54-60 Gy in 30 fractions for other HGG or 45-50.4 Gy for primary spinal disease. Any variances in the radiotherapy dose within 10% of the standard doses outlined above will be discussed with the Study Chair to confirm eligibility prior to study enrollment.

2.3.3 Timing between diagnosis and start of RT: Patients must have started RT within 31 calendar days of initial diagnosis defined as the date of diagnostic biopsy or resection; if a patient underwent two upfront surgeries (e.g., biopsy then resection or debulking), this is the date of the second surgery.

2.3.4 Timing post-RT

• Patients in pre-maintenance phase must enroll and start treatment no later than 21 calendar days post-completion of RT.

• Patients not in pre-maintenance phase must enroll and start treatment no later than 35 calendar days post-completion of RT.

2.4 Organ Function Requirements

2.4.1 Adequate Bone Marrow Function Defined as:

• Peripheral absolute neutrophil count (ANC) = 1000/mm3.

• Platelet count = 100,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).

• Hemoglobin > 8 g/dL (may be transfused).

2.4.2 Adequate Renal Function Defined as

• Creatinine clearance or radioisotope GFR = 70ml/min/1.73 m2 OR

• Maximum serum creatinine based on age/gender as follows: 10 to < 13 yrs=1.2 mg/dL for males and females. 13 to < 16 yrs=1.5 mg/dL for males and 1.4 mg/dL for females.

2.4.3 Adequate Liver Function Defined as:

• Total bilirubin must be = 1.5 × institutional ULN.

• AST(SGOT)/ALT(SGPT) < 3 × institutional ULN.

• Alkaline Phosphatase < 3 × institutional ULN. 2.4.4 Informed consent: All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.

Exclusion Criteria:

1. Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entered on this study due to unknown potential risks of fetal and teratogenic adverse events as seen in animal studies. Pregnancy tests must be obtained in girls who are post-menarchal. Patients of childbearing or child fathering potential must agree to use one highly effective method of contraception while being treated on this study and for 3 months after completing therapy. A woman is considered of childbearing potential if she is fertile, following menarche and until becoming post-menopausal unless permanently sterile. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy. Male participants should refrain from sperm donation throughout the duration of treatment and for 3 months after completion of therapy.

A highly effective contraception method is defined as one that results in a low failure rate (<1% per year) when used consistently and correctly. The following are considered highly effective contraception methods:

• Combined estrogen and progesterone containing hormonal contraception associated with inhibition of ovulation.

• Progesterone-only hormonal contraception associated with inhibition of ovulation.

• Intra Uterine Device (IUD).

• Intra uterine hormone releasing system.

• Bilateral tubal occlusion.

• Vasectomized partner.

• Sexual abstinence (avoiding heterosexual intercourse).

• The following contraceptive measures are NOT considered effective:

• Progesterone-only hormonal contraception (birth control pill) that that does NOT stop ovulation.

• Male or female condom with or without spermicide.

• Cap, diaphragm, or sponge with spermicide.

2. Using the following types of concomitant medications:

• Corticosteroids: Patients receiving corticosteroids are eligible. The use of corticosteroids must be reported.

• Investigational Drugs: Patients who are currently receiving another investigational drug are not eligible.

• Anti-cancer Agents: Concurrent anti-cancer agents are not allowed with the exception of temozolomide given concurrently with RT and as post RT maintenance therapy.

• Anticonvulsants: Patients who are receiving enzyme inducing anticonvulsants that are strong inducers of CYP3A4/5 are not eligible.

• Strong CYP3A4/5 inducers: Patients who are receiving strong inducers of CYP3A4/5 are not eligible. Strong inducers of CYP3A4/5 should be avoided from 14 days prior to or 5 half-lives (whichever is longer) enrollment to the end of the study.

• Patients who are receiving medications known to prolong QTc interval are not eligible

• Selective serotonin reuptake inhibitors (SSRIs) such as citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), sertraline (Zoloft) should be used with caution but are not contraindicated.

• Anticoagulants: patients who are receiving therapeutic anticoagulation with warfarin are not eligible.

3. Other Criteria

• Infection: Patients who have an uncontrolled infection are not eligible.

• Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study are not eligible.

• Patients with known clinically significant active malabsorption syndrome or other condition that could affect absorption are not eligible.

• Patients with malignancy related to HIV or solid organ transplant: known history of HIV, HBV surface antigen positivity or positive HCV antibody are not eligible. Viral testing is not required unless clinically indicated in patients without a known history.

• Patients with prior or ongoing clinically significant illness, medical or psychiatric condition, that, in the investigator's opinion, could affect the safety of the subject, or could impair the assessment of study results are not eligible.

• Patients with any prior solid organ transplant are not eligible.

• Patients with secondary/radiation-related HGG are not eligible.

• Patients with metastatic/disseminated HGG who have received CSI are not eligible.

Related Conditions & MeSH terms

• Astrocytoma
• Astrocytoma, Grade III
• Astrocytoma, Grade IV
• Diffuse Intrinsic Pontine Glioma
• Diffuse Midline Glioma, H3 K27M-Mutant
• Glioblastoma
• Glioma
• High Grade Glioma
• IDH1 Mutation
• Metastatic Brain Tumor
• Oligodendroglioma
• Spinal Tumor
• WHO Grade III Glioma

Intervention

Drug:
• Olutasidenib + TMZ
Olutasidenib 150 mg PO BID + Temozolomide 200 mg/m2 PO QD

Locations

Country	Name	City	State
Australia	Perth Children's Hospital	Perth	Western Australia
Australia	Sydney Children's Hospital	Randwick	New South Wales
Australia	Queensland Children's Hospital	South Brisbane	Queensland
Canada	Montreal Children's Hospital	Montréal	Quebec
Canada	The Hospital for Sick Children (SickKids)	Toronto	Ontario
Germany	Hopp Children's Cancer Center at NCT Heidelberg (KiTZ)	Heidelberg	Baden-Württemberg
Netherlands	Princess Máxima Center	Utrecht
United Kingdom	Great Ormond Street Hospital	London
United States	Children's Hospital Colorado	Aurora	Colorado
United States	Susan Chi	Boston	Massachusetts
United States	Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	Nationwide Children's Hospital	Columbus	Ohio
United States	Duke University Health System	Durham	North Carolina
United States	Texas Children's Hospital	Houston	Texas
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	Seattle Children's Hospital	Seattle	Washington
United States	Children's National Medical Center	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
Rigel Pharmaceuticals	Nationwide Children's Hospital

Countries where clinical trial is conducted

United States,  Australia,  Canada,  Germany,  Netherlands,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Establish the RP2D of Olutasidenib and Temozolomide (Feasibility cohort)	To identify the dose of olutasidenib that is feasible when given post-RT in combination with temozolomide as maintenance therapy in pediatric and young adult patients newly diagnosed with IDH1-mutant high-grade glioma	Completion of cycle 1 (28 days) for 6-24 patients
Primary	Assess Progression-Free Survival (PFS) in Grade 3 IDH1-mutant Astrocytoma (Stratum A)	To assess the post-RT efficacy of olutasidenib in newly diagnosed patients with WHO Grade 3 IDH1-mutant Astrocytoma treated with maintenance olutasidenib and temozolomide for 13 cycles followed by 13 cycles of single agent olutasidenib compared to molecularly-stratified and matched historical controls	From date of diagnosis until date of Progressive Disease or death due to any cause or date of last follow-up, assessed up 24 months
Primary	Maximum plasma concentration [Cmax] of Olutasidenib	To characterize the plasma pharmacokinetic (PK) properties of olutasidenib in pediatric patients (e.g., 12 to < 18 years of age), administered in combination with temozolomide (first year) and as single agent (second year) as maintenance chemotherapy by measuring the Maximum Concentration [Cmax] and Area Under the Curve (AUC) of olutasidenib in plasma (All strata).	From Day 1 of treatment until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 24 months
Secondary	Evaluate objective response rate (ORR) in HGG (All Strata)	Evaluate the radiographic objective response rate (ORR) defined as complete response (CR) + partial response (PR) in pediatric and young adult patients newly diagnosed with IDH1-mutant HGG treated with post-RT olutasidenib with temozolomide.	From day 1 of protocol treatment through 30 days following end of protocol treatment
Secondary	Evaluate Health-Related Quality of Life Outcomes (All Strata)	Evaluate health-related quality of life outcomes of pediatric and young adult patients newly-diagnosed with IDH1-mutant HGG treated with post-RT olutasidenib by patient and/or parent reporting at key timepoints in therapy using the patient reported outcomes measurement information system (PROMIS) survey.; These survey systems report scores on a scale of 1(minimum) to 5 (maximum). The scores may reflect frequencies from "1-Never" to "5-Always" or levels of autonomy from "1-With no trouble" to "5-Not able to do". Scores are interpreted differently for the different outcome measures	From pre-maintenance (2 weeks before the first cycle), and at the start of even numbered cycles (each cycle is 28 days) and at the End of Treatment visit (can have up to 26 cycles)
Secondary	Evaluate Overall Survival in IDH1-mutant Grade 3 Astrocytoma (Stratum A)	Determine distribution of OS in pediatric and young adult patients newly-diagnosed with IDH1-mutant Grade 3 Astrocytoma treated with post-RT olutasidenib and temozolomide for 13 cycles followed by 13 cycles of single agent olutasidenib compared to molecularly-stratified and matched historical controls.(Stratum A)	From date of diagnosis until date of death due to any cause or date of last follow-up, assessed up to 60 months
Secondary	Assess Progression-Free Survival in IDH1-mutant Grade 4 Astrocytoma (Stratum B)	To assess the post-RT efficacy of olutasidenib in newly diagnosed patients with WHO Grade 4 IDH1-mutant Astrocytoma treated with maintenance olutasidenib and temozolomide for 13 cycles followed by 13 cycles of single agent olutasidenib compared to molecularly-stratified and matched historical controls	From date of diagnosis until date of Progressive Disease or death due to any cause or date of last follow-up, assessed up 24 months